These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

396 related articles for article (PubMed ID: 31401212)

  • 1. The new entries in the therapeutic armamentarium: The small molecule JAK inhibitors.
    Bechman K; Yates M; Galloway JB
    Pharmacol Res; 2019 Sep; 147():104392. PubMed ID: 31401212
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Are all JAK inhibitors for the treatment of rheumatoid arthritis equivalent? An adjusted indirect comparison of the efficacy of tofacitinib, baricitinib, upadacitinib, and filgotinib.
    Vallez-Valero L; Gasó-Gago I; Marcos-Fendian Á; Garrido-Alejos G; Riera-Magallón A; Plaza Diaz A; Martinez-Molina C; Mangues-Bafalluy MA; Corominas H
    Clin Rheumatol; 2023 Dec; 42(12):3225-3235. PubMed ID: 37831336
    [TBL] [Abstract][Full Text] [Related]  

  • 3. State of the art: approved and emerging JAK inhibitors for rheumatoid arthritis.
    El Jammal T; Sève P; Gerfaud-Valentin M; Jamilloux Y
    Expert Opin Pharmacother; 2021 Feb; 22(2):205-218. PubMed ID: 32967471
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tofacitinib Suppresses Several JAK-STAT Pathways in Rheumatoid Arthritis
    Palmroth M; Kuuliala K; Peltomaa R; Virtanen A; Kuuliala A; Kurttila A; Kinnunen A; Leirisalo-Repo M; Silvennoinen O; Isomäki P
    Front Immunol; 2021; 12():738481. PubMed ID: 34630419
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Janus kinase inhibitors : State of the art in clinical use and future perspectives].
    Alten R; Mischkewitz M; Stefanski AL; Dörner T
    Z Rheumatol; 2020 Apr; 79(3):241-254. PubMed ID: 32219519
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The rationale for Janus kinase inhibitors for the treatment of spondyloarthritis.
    Veale DJ; McGonagle D; McInnes IB; Krueger JG; Ritchlin CT; Elewaut D; Kanik KS; Hendrikx T; Berstein G; Hodge J; Telliez JB
    Rheumatology (Oxford); 2019 Feb; 58(2):197-205. PubMed ID: 29618084
    [TBL] [Abstract][Full Text] [Related]  

  • 7. JAK-Inhibitors for the Treatment of Rheumatoid Arthritis: A Focus on the Present and an Outlook on the Future.
    Angelini J; Talotta R; Roncato R; Fornasier G; Barbiero G; Dal Cin L; Brancati S; Scaglione F
    Biomolecules; 2020 Jul; 10(7):. PubMed ID: 32635659
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Inhibition of the Janus kinase-signal transducer and activator of transcription is a new treatment modality of rheumatoid arthritis].
    Frøling M; Mikkelsen C; Eggertsen PP; Stern M; van de Looij A; Deleuran B
    Ugeskr Laeger; 2017 Oct; 179(44):. PubMed ID: 29084618
    [TBL] [Abstract][Full Text] [Related]  

  • 9. JAK Inhibitors in Rheumatoid Arthritis: Immunomodulatory Properties and Clinical Efficacy.
    Kiełbowski K; Plewa P; Bratborska AW; Bakinowska E; Pawlik A
    Int J Mol Sci; 2024 Jul; 25(15):. PubMed ID: 39125897
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential properties of Janus kinase inhibitors in the treatment of immune-mediated inflammatory diseases.
    Taylor PC; Choy E; Baraliakos X; Szekanecz Z; Xavier RM; Isaacs JD; Strengholt S; Parmentier JM; Lippe R; Tanaka Y
    Rheumatology (Oxford); 2024 Feb; 63(2):298-308. PubMed ID: 37624925
    [TBL] [Abstract][Full Text] [Related]  

  • 11. JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib.
    Traves PG; Murray B; Campigotto F; Galien R; Meng A; Di Paolo JA
    Ann Rheum Dis; 2021 Jul; 80(7):865-875. PubMed ID: 33741556
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical significance of Janus Kinase inhibitor selectivity.
    Choy EH
    Rheumatology (Oxford); 2019 Jun; 58(6):953-962. PubMed ID: 30508136
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacodynamics of Janus kinase inhibitors for the treatment of atopic dermatitis.
    Calabrese L; Chiricozzi A; De Simone C; Fossati B; D'Amore A; Peris K
    Expert Opin Drug Metab Toxicol; 2022 May; 18(5):347-355. PubMed ID: 35796377
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of Janus kinase inhibitors in the treatment of rheumatoid arthritis: a systemic literature review.
    Jegatheeswaran J; Turk M; Pope JE
    Immunotherapy; 2019 Jun; 11(8):737-754. PubMed ID: 30955397
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advance in bone destruction participated by JAK/STAT in rheumatoid arthritis and therapeutic effect of JAK/STAT inhibitors.
    Hu L; Liu R; Zhang L
    Int Immunopharmacol; 2022 Oct; 111():109095. PubMed ID: 35926270
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of Janus Kinase Inhibition on the Treatment of Axial Spondyloarthropathies.
    Hammitzsch A; Lorenz G; Moog P
    Front Immunol; 2020; 11():591176. PubMed ID: 33193430
    [TBL] [Abstract][Full Text] [Related]  

  • 17. JAK-STAT Pathway: A Novel Target to Tackle Viral Infections.
    Ezeonwumelu IJ; Garcia-Vidal E; Ballana E
    Viruses; 2021 Nov; 13(12):. PubMed ID: 34960648
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [JAK inhibition in the treatment of inflammatory rheumatic diseases].
    Šenolt L
    Vnitr Lek; 2023; 69(3):181-188. PubMed ID: 37468313
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic review of janus kinase inhibitors and its clinical implications for the management of rheumatoid arthritis.
    Chandrashekara S
    Expert Opin Drug Metab Toxicol; 2024 Aug; 20(8):741-748. PubMed ID: 38916236
    [TBL] [Abstract][Full Text] [Related]  

  • 20. JAK Inhibitors: What Is New?
    Reddy V; Cohen S
    Curr Rheumatol Rep; 2020 Jul; 22(9):50. PubMed ID: 32700001
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.